A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a breakthrough in dental manufacturing, a new alopecia treatment and an app to help women navigate perimenopause. NEW YORK, July 18, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some

The impact of pharmaceutical tariffs would be "significant," Novartis CEO Vas Narasimhan said. The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff on pharmaceuticals.The long-threatened tariffs will arrive “probably at the end of the month,” the president suggested Tuesday. “We’re going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we’re going to make it a very

KIGALI, RWANDA — Emotions ran high this week at one of the world’s leading HIV science conferences after months of adapting in real-time to funding pullbacks that have shuttered or stalled critical HIV programs. The financial losses and uncertainty came up during many of the sessions at the International AIDS Society (IAS) Conference on HIV Science in the capital of Rwanda. But many attendees also expressed hope, as they’ve done for four decades of advancements and setbacks in HIV medicine, citi

New Delhi: The Fixed Dose Combination (FDC) of popular anti-diabetes medicine Metformin Hydrochloride and Voglibose is set to be excluded from the list of unapproved FDCs notified by the CDSCO in April this year. In a statement before the Delhi High Court over a petition challenging the classification of the combination as an unapproved drug, the Drugs Controller General of India ( DCGI ) has formally stated to exclude the above combination from the notified list. In April this year, the apex dr

Two PEG-based intermediates from BIOPHARMA PEG now listed in FDA DMF, supporting regulatory needs for drug delivery and bioconjugation. WATERTOWN, MA, UNITED STATES, July 18, 2025 / EINPresswire.com / -- BIOPHARMA PEG, a developer of functional polyethylene glycol (PEG) derivatives for pharmaceutical R&D, has announced that two of its PEG-based intermediates have been assigned Drug Master File (DMF) numbers by the U.S. Food and Drug Administration (FDA). The products now listed in the FDA's DMF

EQT X to acquire Adalvo, a rapidly growing, asset-light B2B dossier developer providing market-approval-ready generic drug dossiers to pharmaceutical companies EQT will support Adalvo's next phase of growth, further investing in R&D and innovation, and advancing the operational scale-up of the business Adalvo is uniquely positioned as a one-stop partner, combining strong business development capabilities with a flexible, customer-centric model to meet the bespoke needs of

XIAMEN, China, July 18, 2025 /PRNewswire/ -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between the brain and external devices. This transformative innovation is driving profound societal impact across industries: revolutionizing neurological disease treatment (e.g., epilepsy, Parkinson's, and depression), enhancing educational outcomes through improved focus, and enabling seamless industrial human-robot collaboration. W

New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, NJ, USA I July 17, 2025 I Johnson & Johnson (NYSE: JNJ ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with

New Delhi: Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed

The Broad Institute announced today that Seth Klarman , prominent business leader, investor, philanthropist, and author, will become the next Chair of the Board of Directors, succeeding Eric Schmidt , who has served as Chair of the Board since 2021. Schmidt, who joined the Board of Directors in 2012, will remain on the Board. The Board of Directors also appointed Gerun Riley , President of the Broad Foundation and Mark Nunnelly, Chair of Toolbox to serve as Vice Chairs, and is welcoming Aviv Reg